Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	6.32M 0 5.62M 5.25M 4.78M 9.02M 608M 9.1M 63.47M 24.6M 311M 23.75M 23.23M 998M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	6.32M 0 5.62M 5.25M 4.78M 9.02M 608M 9.1M 63.47M 24.6M 311M 23.75M 23.23M 998M	EV / Sales 2026 *	4.4x	EV / Sales 2027 *	2.43x
Free-Float	72.14%	Yield 2026 *	-	Yield 2027 *	-

09-16	Evogene Ltd. Announces Board Changes	CI
09-11	L.I.A. Pure Capital Intends to Commence a Special Tender Offer to Evogene	CI
09-04	Evogene Ltd. Approves Board Appointments	CI
08-28	L.I.A. Pure Capital Issues Response to Evogene	CI
08-25	Institutional Shareholder Services and Glass Lewis Makes Recommendations to Shareholders	CI
08-18	Evogene Ltd., Q2 2026 Earnings Call, Aug 18, 2026
08-18	Evogene Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-17	Freightos Names Yaron Eldad as Chief Financial Officer	MT
07-27	L.I.A. Pure Capital Ltd Delivers an Email to Evogene Ltd	CI
07-22	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
07-22	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
07-10	L.I.A. Pure Capital Sends Letter to Evogene	CI
07-08	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
18/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
29/07/21	Evogene : Aegis Capital Starts Evogene at Buy	MT
01/12/20	Evogene : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

09-30	Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance	PR
08-31	Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward	PR
08-25	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees	PR
08-18	Evogene Reports Second Quarter and First Half 2026 Financial Results	PR
08-18	Evogene : Reports Second Quarter and First Half 2026 Financial Results	PU

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	01/12/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	01/01/2022

Evogene Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd

Latest news: Evogene Ltd

Last Transcript: Evogene Ltd

Analysts' recommendations: Evogene Ltd

Press Releases: Evogene Ltd

News in other languages: Evogene Ltd

Quotes and Performance

Managers and Directors: Evogene Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	03/06/2010
Sarit Firon CHM	Chairman	60	01/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD	-0.43%	-5.52%	-	-	6.38M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+21.92%	+74.60%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+4.28%	+34.51%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+352.17%	+689.61%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+26.36%	+33.18%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+3.74%	+100.60%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+19.50%	28.53B
BIONTECH SE	+0.05%	-1.64%	-7.28%	-14.06%	24.34B
Average	-0.25%	-0.59%	+54.39%	+120.28%	43.39B
Weighted average by Cap.	+0.12%	-0.84%	+58.77%	+129.91%

	2026 *	2027 *
Net sales	1.44M 0 1.28M 1.19M 1.09M 2.05M 138M 2.07M 14.41M 5.58M 70.57M 5.39M 5.27M 226M	2.6M 0 2.31M 2.16M 1.97M 3.71M 250M 3.74M 26.09M 10.11M 128M 9.76M 9.55M 410M
Net income	-12.17M -0 -10.81M -10.09M -9.2M -17.35M -1.17B -17.51M -122M -47.32M -598M -45.69M -44.7M -1.92B	-10.2M -0 -9.06M -8.46M -7.71M -14.54M -981M -14.68M -102M -39.67M -501M -38.3M -37.46M -1.61B
Net Debt	-	-